Novel observations with FDOPA-PET imaging after early nigrostriatal damage.
Identifieur interne : 003C71 ( PubMed/Curation ); précédent : 003C70; suivant : 003C72Novel observations with FDOPA-PET imaging after early nigrostriatal damage.
Auteurs : R E Yee [États-Unis] ; I. Irwin ; C. Milonas ; D B Stout ; S C Huang ; K. Shoghi-Jadid ; N. Satyamurthy ; L E Delanney ; D M Togasaki ; K F Farahani ; K. Delfani ; A M Janson ; M E Phelps ; J W Langston ; J R BarrioSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2001.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Animals, Corpus Striatum (metabolism), Corpus Striatum (pathology), Dihydroxyphenylalanine (analogs & derivatives), Dihydroxyphenylalanine (diagnostic use), Disease Models, Animal, Dopamine (deficiency), Female, Fluorine Radioisotopes (diagnostic use), Male, Neural Pathways, Neurotoxins, Parkinsonian Disorders (chemically induced), Parkinsonian Disorders (metabolism), Parkinsonian Disorders (pathology), Parkinsonian Disorders (radionuclide imaging), Saimiri, Substantia Nigra (metabolism), Substantia Nigra (pathology), Tomography, Emission-Computed.
- MESH :
- chemical , analogs & derivatives : Dihydroxyphenylalanine.
- chemical , deficiency : Dopamine.
- chemical , diagnostic use : Dihydroxyphenylalanine, Fluorine Radioisotopes.
- chemical : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Neurotoxins.
- chemically induced : Parkinsonian Disorders.
- metabolism : Corpus Striatum, Parkinsonian Disorders, Substantia Nigra.
- pathology : Corpus Striatum, Parkinsonian Disorders, Substantia Nigra.
- radionuclide imaging : Parkinsonian Disorders.
- Animals, Disease Models, Animal, Female, Male, Neural Pathways, Saimiri, Tomography, Emission-Computed.
Abstract
Striatal 6-[18F]fluoro-L-DOPA (FDOPA) kinetic rate constants were measured by positron emission tomography (PET) in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys. After scanning, stereological counts of dopaminergic neurons were done in substantia nigra, and dopamine (DA) and metabolite concentrations were determined in the caudate, putamen, and substantia nigra. Graded doses of MPTP produced animals with mild to moderate reductions (10-35%) in dopaminergic neurons, where the percent of cell loss was proportional to the amount of MPTP given. Striatal DA and metabolite concentrations were relatively unchanged in animals given 1.0 and 1.5 mg/kg of MPTP, but were significantly reduced after 2.0 mg/kg of MPTP. All animals injected with a single dose of MPTP showed no overt signs of parkinsonism. In contrast, DA and metabolite concentrations in the substantia nigra were significantly reduced for all MPTP-treated animals. Reduction of dopaminergic indices in the substantia nigra did not parallel reductions in the striatum, indicating differential sensitivity of the nigrostriatal pathway to the neurotoxic effects of MPTP. The percent change in FDOPA uptake (Ki) and decarboyxlation (k3) after MPTP showed significant positive correlations to striatal DA levels, but not to the number of dopaminergic neurons. This suggests that FDOPA is a good index of striatal DA levels.
PubMed: 11746613
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003C71
Links to Exploration step
pubmed:11746613Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Novel observations with FDOPA-PET imaging after early nigrostriatal damage.</title><author><name sortKey="Yee, R E" sort="Yee, R E" uniqKey="Yee R" first="R E" last="Yee">R E Yee</name><affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California 90095-6948, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California 90095-6948</wicri:regionArea></affiliation></author><author><name sortKey="Irwin, I" sort="Irwin, I" uniqKey="Irwin I" first="I" last="Irwin">I. Irwin</name></author><author><name sortKey="Milonas, C" sort="Milonas, C" uniqKey="Milonas C" first="C" last="Milonas">C. Milonas</name></author><author><name sortKey="Stout, D B" sort="Stout, D B" uniqKey="Stout D" first="D B" last="Stout">D B Stout</name></author><author><name sortKey="Huang, S C" sort="Huang, S C" uniqKey="Huang S" first="S C" last="Huang">S C Huang</name></author><author><name sortKey="Shoghi Jadid, K" sort="Shoghi Jadid, K" uniqKey="Shoghi Jadid K" first="K" last="Shoghi-Jadid">K. Shoghi-Jadid</name></author><author><name sortKey="Satyamurthy, N" sort="Satyamurthy, N" uniqKey="Satyamurthy N" first="N" last="Satyamurthy">N. Satyamurthy</name></author><author><name sortKey="Delanney, L E" sort="Delanney, L E" uniqKey="Delanney L" first="L E" last="Delanney">L E Delanney</name></author><author><name sortKey="Togasaki, D M" sort="Togasaki, D M" uniqKey="Togasaki D" first="D M" last="Togasaki">D M Togasaki</name></author><author><name sortKey="Farahani, K F" sort="Farahani, K F" uniqKey="Farahani K" first="K F" last="Farahani">K F Farahani</name></author><author><name sortKey="Delfani, K" sort="Delfani, K" uniqKey="Delfani K" first="K" last="Delfani">K. Delfani</name></author><author><name sortKey="Janson, A M" sort="Janson, A M" uniqKey="Janson A" first="A M" last="Janson">A M Janson</name></author><author><name sortKey="Phelps, M E" sort="Phelps, M E" uniqKey="Phelps M" first="M E" last="Phelps">M E Phelps</name></author><author><name sortKey="Langston, J W" sort="Langston, J W" uniqKey="Langston J" first="J W" last="Langston">J W Langston</name></author><author><name sortKey="Barrio, J R" sort="Barrio, J R" uniqKey="Barrio J" first="J R" last="Barrio">J R Barrio</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2001">2001</date><idno type="RBID">pubmed:11746613</idno><idno type="pmid">11746613</idno><idno type="wicri:Area/PubMed/Corpus">003C71</idno><idno type="wicri:Area/PubMed/Curation">003C71</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Novel observations with FDOPA-PET imaging after early nigrostriatal damage.</title><author><name sortKey="Yee, R E" sort="Yee, R E" uniqKey="Yee R" first="R E" last="Yee">R E Yee</name><affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California 90095-6948, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California 90095-6948</wicri:regionArea></affiliation></author><author><name sortKey="Irwin, I" sort="Irwin, I" uniqKey="Irwin I" first="I" last="Irwin">I. Irwin</name></author><author><name sortKey="Milonas, C" sort="Milonas, C" uniqKey="Milonas C" first="C" last="Milonas">C. Milonas</name></author><author><name sortKey="Stout, D B" sort="Stout, D B" uniqKey="Stout D" first="D B" last="Stout">D B Stout</name></author><author><name sortKey="Huang, S C" sort="Huang, S C" uniqKey="Huang S" first="S C" last="Huang">S C Huang</name></author><author><name sortKey="Shoghi Jadid, K" sort="Shoghi Jadid, K" uniqKey="Shoghi Jadid K" first="K" last="Shoghi-Jadid">K. Shoghi-Jadid</name></author><author><name sortKey="Satyamurthy, N" sort="Satyamurthy, N" uniqKey="Satyamurthy N" first="N" last="Satyamurthy">N. Satyamurthy</name></author><author><name sortKey="Delanney, L E" sort="Delanney, L E" uniqKey="Delanney L" first="L E" last="Delanney">L E Delanney</name></author><author><name sortKey="Togasaki, D M" sort="Togasaki, D M" uniqKey="Togasaki D" first="D M" last="Togasaki">D M Togasaki</name></author><author><name sortKey="Farahani, K F" sort="Farahani, K F" uniqKey="Farahani K" first="K F" last="Farahani">K F Farahani</name></author><author><name sortKey="Delfani, K" sort="Delfani, K" uniqKey="Delfani K" first="K" last="Delfani">K. Delfani</name></author><author><name sortKey="Janson, A M" sort="Janson, A M" uniqKey="Janson A" first="A M" last="Janson">A M Janson</name></author><author><name sortKey="Phelps, M E" sort="Phelps, M E" uniqKey="Phelps M" first="M E" last="Phelps">M E Phelps</name></author><author><name sortKey="Langston, J W" sort="Langston, J W" uniqKey="Langston J" first="J W" last="Langston">J W Langston</name></author><author><name sortKey="Barrio, J R" sort="Barrio, J R" uniqKey="Barrio J" first="J R" last="Barrio">J R Barrio</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2001" type="published">2001</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Animals</term><term>Corpus Striatum (metabolism)</term><term>Corpus Striatum (pathology)</term><term>Dihydroxyphenylalanine (analogs & derivatives)</term><term>Dihydroxyphenylalanine (diagnostic use)</term><term>Disease Models, Animal</term><term>Dopamine (deficiency)</term><term>Female</term><term>Fluorine Radioisotopes (diagnostic use)</term><term>Male</term><term>Neural Pathways</term><term>Neurotoxins</term><term>Parkinsonian Disorders (chemically induced)</term><term>Parkinsonian Disorders (metabolism)</term><term>Parkinsonian Disorders (pathology)</term><term>Parkinsonian Disorders (radionuclide imaging)</term><term>Saimiri</term><term>Substantia Nigra (metabolism)</term><term>Substantia Nigra (pathology)</term><term>Tomography, Emission-Computed</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Dihydroxyphenylalanine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="deficiency" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Dihydroxyphenylalanine</term><term>Fluorine Radioisotopes</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Neurotoxins</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Corpus Striatum</term><term>Parkinsonian Disorders</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Corpus Striatum</term><term>Parkinsonian Disorders</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Female</term><term>Male</term><term>Neural Pathways</term><term>Saimiri</term><term>Tomography, Emission-Computed</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Striatal 6-[18F]fluoro-L-DOPA (FDOPA) kinetic rate constants were measured by positron emission tomography (PET) in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys. After scanning, stereological counts of dopaminergic neurons were done in substantia nigra, and dopamine (DA) and metabolite concentrations were determined in the caudate, putamen, and substantia nigra. Graded doses of MPTP produced animals with mild to moderate reductions (10-35%) in dopaminergic neurons, where the percent of cell loss was proportional to the amount of MPTP given. Striatal DA and metabolite concentrations were relatively unchanged in animals given 1.0 and 1.5 mg/kg of MPTP, but were significantly reduced after 2.0 mg/kg of MPTP. All animals injected with a single dose of MPTP showed no overt signs of parkinsonism. In contrast, DA and metabolite concentrations in the substantia nigra were significantly reduced for all MPTP-treated animals. Reduction of dopaminergic indices in the substantia nigra did not parallel reductions in the striatum, indicating differential sensitivity of the nigrostriatal pathway to the neurotoxic effects of MPTP. The percent change in FDOPA uptake (Ki) and decarboyxlation (k3) after MPTP showed significant positive correlations to striatal DA levels, but not to the number of dopaminergic neurons. This suggests that FDOPA is a good index of striatal DA levels.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">11746613</PMID><DateCreated><Year>2001</Year><Month>12</Month><Day>17</Day></DateCreated><DateCompleted><Year>2002</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>5</Issue><PubDate><Year>2001</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Novel observations with FDOPA-PET imaging after early nigrostriatal damage.</ArticleTitle><Pagination><MedlinePgn>838-48</MedlinePgn></Pagination><Abstract><AbstractText>Striatal 6-[18F]fluoro-L-DOPA (FDOPA) kinetic rate constants were measured by positron emission tomography (PET) in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys. After scanning, stereological counts of dopaminergic neurons were done in substantia nigra, and dopamine (DA) and metabolite concentrations were determined in the caudate, putamen, and substantia nigra. Graded doses of MPTP produced animals with mild to moderate reductions (10-35%) in dopaminergic neurons, where the percent of cell loss was proportional to the amount of MPTP given. Striatal DA and metabolite concentrations were relatively unchanged in animals given 1.0 and 1.5 mg/kg of MPTP, but were significantly reduced after 2.0 mg/kg of MPTP. All animals injected with a single dose of MPTP showed no overt signs of parkinsonism. In contrast, DA and metabolite concentrations in the substantia nigra were significantly reduced for all MPTP-treated animals. Reduction of dopaminergic indices in the substantia nigra did not parallel reductions in the striatum, indicating differential sensitivity of the nigrostriatal pathway to the neurotoxic effects of MPTP. The percent change in FDOPA uptake (Ki) and decarboyxlation (k3) after MPTP showed significant positive correlations to striatal DA levels, but not to the number of dopaminergic neurons. This suggests that FDOPA is a good index of striatal DA levels.</AbstractText><CopyrightInformation>Copyright 2001 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yee</LastName><ForeName>R E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California 90095-6948, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irwin</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Milonas</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Stout</LastName><ForeName>D B</ForeName><Initials>DB</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>S C</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Shoghi-Jadid</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Satyamurthy</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Delanney</LastName><ForeName>L E</ForeName><Initials>LE</Initials></Author><Author ValidYN="Y"><LastName>Togasaki</LastName><ForeName>D M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Farahani</LastName><ForeName>K F</ForeName><Initials>KF</Initials></Author><Author ValidYN="Y"><LastName>Delfani</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Janson</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Phelps</LastName><ForeName>M E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Langston</LastName><ForeName>J W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Barrio</LastName><ForeName>J R</ForeName><Initials>JR</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS 33356</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005462">Fluorine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009498">Neurotoxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>2C598205QX</RegistryNumber><NameOfSubstance UI="C043437">fluorodopa F 18</NameOfSubstance></Chemical><Chemical><RegistryNumber>63-84-3</RegistryNumber><NameOfSubstance UI="D004295">Dihydroxyphenylalanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9P21XSP91P</RegistryNumber><NameOfSubstance UI="D015632">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2001 Sep;16(5):804-6</RefSource><PMID Version="1">11746608</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015632">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003342">Corpus Striatum</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004295">Dihydroxyphenylalanine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000031">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004298">Dopamine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000172">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005462">Fluorine Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009434">Neural Pathways</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009498">Neurotoxins</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020734">Parkinsonian Disorders</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012453">Saimiri</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013378">Substantia Nigra</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D014055">Tomography, Emission-Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>12</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>2</Month><Day>14</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>12</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11746613</ArticleId><ArticleId IdType="pii">10.1002/mds.1168</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003C71 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003C71 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:11746613
|texte= Novel observations with FDOPA-PET imaging after early nigrostriatal damage.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:11746613" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |